Showing 3481-3490 of 5646 results for "".
- European Commission Approves Mynzepli as a Biosimilar to Eyleahttps://modernod.com/news/european-commission-approves-mynzepli-as-a-biosimilar-to-eylea/2484127/The European Commission has granted marketing authorization for Mynzepli (aflibercept), a biosimilar to Eylea, developed by Alvotech in partnership with Advanz Pharma. The centralized authorization applies t
- FDA Clears IND for Opus Genetics’ OPGx-BEST1 Gene Therapy Candidatehttps://modernod.com/news/fda-clears-ind-for-opus-genetics-opgx-best1-gene-therapy-candidate/2484123/Opus Genetics announced that the FDA has accepted its investigational new drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal diseases (IRDs). The company now plans to initiate a Phase 1/2 clinical trial in the second
- Prevent Blindness Forms New Diabetes + the Eyes Advisory Committeehttps://modernod.com/news/prevent-blindness-forms-new-diabetes-the-eyes-advisory-committee/2482934/Prevent Blindness has created a new Diabetes + the Eyes Advisory Committee. The volunteer panel will guide national initiatives to raise awareness, expand access to care, and improve early detection of diabetes-related eye diseases.
- VSY Biotechnology Launches Enova Hydrophobic IOLs with Rotaryjet Technologyhttps://modernod.com/news/vsy-biotechnology-launches-enova-hydrophobic-iols-with-rotaryjet-technology/2482932/VSY Biotechnology has launched the Enova Hydrophobic IOLs, with the company's Rotaryjet Preloaded Delivery System. This technology is designed to provide ophthalmic surgeons with a safer, more efficient, and user-friendly solution for lens implantation. The patented Rotary
- New Research Highlights Lumenis Dynamic Muscle Stimulation Technology in Managing Lower Lid Laxity and Blinking Qualityhttps://modernod.com/news/new-research-highlights-lumenis-dynamic-muscle-stimulation-technology-in-managing-lower-lid-laxity-and-blinking-quality/2482929/New findings demonstrating Lumenis’s Dynamic Muscle Stimulation technology (DMSt) can effectively address lower lid laxity and improve blinking quality in patients with dry eye disease (DED).[1]. According to Lumenis,
- Mark Maire Appointed CEO of Rebionhttps://modernod.com/news/mark-maire-appointed-ceo-of-rebion/2482920/Rebion, a provider of neuro-visual diagnostics and digital retinal imaging technologies, announced the appointment of Mark Maire as Chief Executive Officer. Mr. Maire brings more than two decades of commercial leadership and strategic growth experience, including the sale of TrueVi
- Market Scope: Investor Interest in Ophthalmology Remains Stronghttps://modernod.com/news/market-scope-investor-interest-in-ophthalmology-remains-strong/2482919/The ophthalmic industry continues to command the attention of investors with $620 million raised across 13 transactions in Q2 2025, according to Market Scope’s latest Ophthalmic Deals Report. However, the investment dollars are down from Q2-2024 and
- Alcon to Acquire Staar Surgical for $1.5 Billionhttps://modernod.com/news/alcon-to-acquire-staar-surgical-for-15-billion/2482917/In a major deal to expand its refractive portfolio and continue its spree of acquisitions, Alcon has agreed to acquire Staar Surgical, maker of the Implantable Collamer Lens (ICL). The acquisition includes the EVO family of l
- Genentech Unveils 5-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatmenthttps://modernod.com/news/genentech-unveils-five-year-data-for-susvimo-long-term-efficacy-and-durability-in-wet-amd-treatment/2482915/Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The fin
- Topcon Healthcare Acquires Intelligent Retinal Imaging Systemshttps://modernod.com/news/topcon-healthcare-acquires-intelligent-retinal-imaging-systems-to-enhance-connected-care-across-primary-and-eye-care/2482909/Topcon Healthcare announced the acquisition of Intelligent Retinal Imaging Systems (IRIS), a US-based provider of cloud-based retinal screening technology. FInancial terms of the deal were not disclosed. IRIS bri